The new EU Clinical Trials Regulation (No 536/2014), which will be applicable in the near future, would revise the current framework of clinical trials and guarantee uniformity and harmonization within the EU. 

The recent developments in the UK (BREXIT referendum) have raised a lot of questions and panic within all major sectors, and pharma industry is no exception. Though the full impact of these developments on pharma industry is difficult to visualize, but the complexities and the consequences involved need to be understood to ensure drug safety and quality. Hence it is demanding for all to keep them abreast with the latest in the field.

European Pharmacovigilance and clinical trials conference 2016 will provide an opportunity to all its attendees to discuss, share and stay updated with present state of affairs in Pharmacovigilance and clinical trials. It will also allow all its participants to discuss the various developments, challenges faced and innovations in the field. The conference will attempt to explore the reforms required to enhance drug safety and public health. The conference will also provide all its participants an opportunity to network with various pharmaceutical industries; clinical research organizations and PV service providers.

It gives us a great pleasure welcoming you to the European Pharmacovigilance and Clinical Trials 2016 conference